Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1992 1
1997 1
1998 2
1999 2
2000 2
2004 2
2005 1
2006 6
2007 1
2008 1
2009 6
2010 1
2011 1
2012 5
2013 7
2014 11
2015 3
2016 11
2017 8
2018 8
2019 4
2020 4
2021 7
2022 8
2023 9
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.
Zhu G, Pei L, Xia H, Tang Q, Bi F. Zhu G, et al. Mol Cancer. 2021 Nov 6;20(1):143. doi: 10.1186/s12943-021-01441-4. Mol Cancer. 2021. PMID: 34742312 Free PMC article. Review.
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. ...Due to the presence of KRAS mutations, this group of CRC patients requires more precise therapies. However, KRAS was historically thought to be an undruggable target until th …
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. ...Due to the presence of KRAS mutations, th …
Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going.
Sun C, España S, Buges C, Layos L, Hierro C, Manzano JL. Sun C, et al. Clin Colorectal Cancer. 2022 Jun;21(2):71-79. doi: 10.1016/j.clcc.2022.01.009. Epub 2022 Feb 3. Clin Colorectal Cancer. 2022. PMID: 35277355 Review.
In recent years, studies on the molecular typing of colorectal cancer have matured, and the V-raf murine sarcoma viral oncogene homolog B (BRAF) of the mitogen-activated protein kinase pathway has been shown to be an important effector molecule of this pathway and r …
In recent years, studies on the molecular typing of colorectal cancer have matured, and the V-raf murine sarcoma viral oncogen …
Quality and consistency of clinical practice guideline recommendations for PET/CT and PET: a systematic appraisal.
Li Q, Hou W, Wu M, Li L, Su M, Ma B, Cui F, Ren Y, Xu J, Zou K, Tian R, Sun X. Li Q, et al. Eur Radiol. 2023 Nov;33(11):7879-7889. doi: 10.1007/s00330-023-09786-8. Epub 2023 Jun 14. Eur Radiol. 2023. PMID: 37314473
Considerable inconsistencies in the direction of whether to support the use of FDG PET/CT were observed in 10 (20.1%) indications pertaining to 8 cancer types: head and neck cancer (treatment response assessment), colorectal cancer (staging in patients with stages I-III di …
Considerable inconsistencies in the direction of whether to support the use of FDG PET/CT were observed in 10 (20.1%) indications pertaining …
Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer.
Lo L, Patel D, Townsend AR, Price TJ. Lo L, et al. Expert Opin Drug Metab Toxicol. 2015;11(12):1907-24. doi: 10.1517/17425255.2015.1112787. Epub 2015 Nov 16. Expert Opin Drug Metab Toxicol. 2015. PMID: 26572750 Review.
INTRODUCTION: Integration of targeted therapy and additional chemotherapy options has improved median overall survival (OS) in patients with unresectable metastatic colorectal cancer (mCRC). Cetuximab and panitumumab are examples of targeted therapies, specif …
INTRODUCTION: Integration of targeted therapy and additional chemotherapy options has improved median overall survival (OS) in patien …
Management of Brain Metastases: A Review of Novel Therapies.
Bellur S, Khosla AA, Ozair A, Kotecha R, McDermott MW, Ahluwalia MS. Bellur S, et al. Semin Neurol. 2023 Dec;43(6):845-858. doi: 10.1055/s-0043-1776782. Epub 2023 Nov 27. Semin Neurol. 2023. PMID: 38011864 Free article. Review.
Brain metastases (BMs) represent the most common intracranial tumors in adults, and most commonly originate from lung, followed by breast, melanoma, kidney, and colorectal cancer. Management of BM is individualized based on the size and number of brain metastases, the exte …
Brain metastases (BMs) represent the most common intracranial tumors in adults, and most commonly originate from lung, followed by breast, m …
Current management of familial adenomatous polyposis.
Lauricella S, Rausa E, Pellegrini I, Ricci MT, Signoroni S, Palassini E, Cavalcoli F, Pasanisi P, Colombo C, Vitellaro M. Lauricella S, et al. Expert Rev Anticancer Ther. 2024 Jun;24(6):363-377. doi: 10.1080/14737140.2024.2344649. Epub 2024 May 26. Expert Rev Anticancer Ther. 2024. PMID: 38785081 Review.
Integrating genetic advances, innovative surveillance techniques, and emerging therapeutic modalities will contribute to improving outcomes and quality of life for FAP individuals....
Integrating genetic advances, innovative surveillance techniques, and emerging therapeutic modalities will contribute to improving ou …
The Unmet Needs of the Diagnosis, Staging, and Treatment of Gastrointestinal Tumors.
Halama N, Haberkorn U. Halama N, et al. Semin Nucl Med. 2020 Sep;50(5):389-398. doi: 10.1053/j.semnuclmed.2020.06.003. Epub 2020 Jul 8. Semin Nucl Med. 2020. PMID: 32768003 Review.
The molecular stratification of solid tumors has led to improved clinical outcomes and is a key part in the diagnostic workup. Beyond mutational spectra (like Rat sarcoma [RAS] mutations or tumor mutational burden), the investigation of the immunological microenvironment h …
The molecular stratification of solid tumors has led to improved clinical outcomes and is a key part in the diagnostic workup. Beyond mutati …
Management of hepatic metastases.
Choti MA, Bulkley GB. Choti MA, et al. Liver Transpl Surg. 1999 Jan;5(1):65-80. doi: 10.1002/lt.500050113. Liver Transpl Surg. 1999. PMID: 9873095 Free article. Review.
Although the liver is the most common site of metastatic disease from a variety of tumor types, isolated hepatic metastases most commonly occur from colorectal cancer and, less frequently, from neuroendocrine tumors, gastrointestinal sarcoma, ocular melanoma, and ot …
Although the liver is the most common site of metastatic disease from a variety of tumor types, isolated hepatic metastases most commonly oc …
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.
Bebb DG, Banerji S, Blais N, Desmeules P, Gill S, Grin A, Feilotter H, Hansen AR, Hyrcza M, Krzyzanowska M, Melosky B, Noujaim J, Purgina B, Ruether D, Simmons CE, Soulieres D, Torlakovic EE, Tsao MS. Bebb DG, et al. Curr Oncol. 2021 Jan 15;28(1):523-548. doi: 10.3390/curroncol28010053. Curr Oncol. 2021. PMID: 33467570 Free PMC article.
We provide a Canadian consensus on when and how to test for NTRK gene fusions and when to consider treatment with a TRK inhibitor. We focus on five tumour types: thyroid carcinoma, colorectal carcinoma, non-small cell lung carcinoma, soft tissue sarcoma, and salivar …
We provide a Canadian consensus on when and how to test for NTRK gene fusions and when to consider treatment with a TRK inhibitor. We focus …
Evolving role of regorafenib for the treatment of advanced cancers.
Grothey A, Blay JY, Pavlakis N, Yoshino T, Bruix J. Grothey A, et al. Cancer Treat Rev. 2020 Jun;86:101993. doi: 10.1016/j.ctrv.2020.101993. Epub 2020 Feb 20. Cancer Treat Rev. 2020. PMID: 32199197 Free article. Review.
Regorafenib is an oral tyrosine kinase inhibitor (TKI) approved for the treatment of refractory metastatic colorectal cancer (mCRC), advanced gastrointestinal stromal tumors (GIST) previously treated with imatinib and sunitinib, and unresectable hepatocellular carcinoma (H …
Regorafenib is an oral tyrosine kinase inhibitor (TKI) approved for the treatment of refractory metastatic colorectal cancer (mCRC), …
109 results